MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s40478-024-01838-4

Медицинская библиотека · Acta neuropathologica communications · 2024

Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.

Apps John R, Gonzalez-Meljem Jose Mario, Guiho Romain, Pickles Jessica C, Prince Eric, Schwalbe Edward, Joshi Nikhil, Stone Thomas J, Ogunbiyi Olumide, Chalker Jane, Bassey Akang, Otto Georg, Davies Rosalind, Hughes Debbie, Brandner Sebastian, Tan Enrica, Lee Victoria, Hayhurst Caroline, Kline Cassie, Castellano Sergi, Hankinson Todd, Deutschbein Timo, Jacques Thomas S, Martinez-Barbera Juan Pedro

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

The two types of craniopharyngioma, adamantinomatous (ACP) and papillary (PCP), are clinically relevant tumours in children and adults. Although the biology of primary craniopharyngioma is starting to be unravelled, little is known about the biology of recurrence. To fill this gap in knowledge, we have analysed through methylation array, RNA sequencing and pERK1/2 immunohistochemistry a cohort of paired primary and recurrent samples (32 samples from 14 cases of ACP and 4 cases of PCP). We show the presence of copy number alterations and clonal evolution across recurrence in 6 cases of ACP, and analysis of additional whole genome sequencing data from the Children's Brain Tumour Network confirms chromosomal arm copy number changes in at least 7/67 ACP cases. The activation of the MAPK/ERK pathway, a feature previously shown in primary ACP, is observed in all but one recurrent cases of ACP. The only ACP without MAPK activation is an aggressive case of recurrent malignant human craniopharyngioma harbouring a CTNNB1 mutation and loss of TP53. Providing support for a functional role of this TP53 mutation, we show that Trp53 loss in a murine model of ACP results in aggressive tumours and reduced mouse survival. Finally, we characterise the tumour immune infiltrate showing differences in the cellular composition and spatial distribution between ACP and PCP. Together, these analyses have revealed novel insights into recurrent craniopharyngioma and provided preclinical evidence supporting the evaluation of MAPK pathway inhibitors and immunomodulatory approaches in clinical trials in against recurrent ACP.

Для цитирования: Apps John R, Gonzalez-Meljem Jose Mario, Guiho Romain, Pickles Jessica C, Prince Eric, Schwalbe Edward, Joshi Nikhil, Stone Thomas J, Ogunbiyi Olumide, Chalker Jane, Bassey Akang, Otto Georg, Davies Rosalind, Hughes Debbie, Brandner Sebastian, Tan Enrica, Lee Victoria, Hayhurst Caroline, Kline Cassie, Castellano Sergi, Hankinson Todd, Deutschbein Timo, Jacques Thomas S, Martinez-Barbera Juan Pedro. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.. Acta neuropathologica communications. 2024. DOI: 10.1186/s40478-024-01838-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.